v3.25.3
Commitments and Contingencies - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Apr. 16, 2025
Dec. 20, 2024
Dec. 19, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Loss Contingencies [Line Items]                
Accrued clinical and contract manufacturing expense       $ 4,400   $ 4,400   $ 3,600
Incurred collaboration and supply agreement expense       0 $ 300 0 $ 1,000  
Research and development       $ 14,345 $ 9,997 $ 71,942 $ 36,683  
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                
Loss Contingencies [Line Items]                
Research and development $ 38,000 $ 6,000            
Non-refundable payment due     $ 38,000          
Upfront payment period     120 days          
Royalty period     10 years          
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Development Milestones                
Loss Contingencies [Line Items]                
Maximum aggregate milestone payments     $ 265,000          
WuXi Biologics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Commercial Milestones                
Loss Contingencies [Line Items]                
Maximum aggregate milestone payments     $ 540,000